Goodnick P J, Meltzer H Y
Schizophr Bull. 1984;10(1):30-48. doi: 10.1093/schbul/10.1.30.
Studies that compare the treatment response of patients diagnosed as primary affective disorder or schizoaffective disorder are reviewed. Although relatively few controlled or uncontrolled studies of the chemotherapy of schizoaffective disorders have been conducted, available evidence suggests that: (1) lithium carbonate is effective in the initial treatment of both schizoaffective mania and mania; (2) antidepressants alone, neuroleptics alone, or their combination can be effective in the initial treatment of both schizoaffective depression and primary depression; and (3) prophylactic administration of lithium carbonate may reduce the frequency and duration of relapse in both schizoaffective manic and schizoaffective depressed patients. Thus, treatment studies indicate that the schizoaffective disorders are very similar to the primary affective disorders with regard to response to pharmacologic treatment. Evidence from this laboratory that schizoaffective manic patients respond more slowly than manic patients to lithium or neuroleptic treatment is presented.
对比较被诊断为原发性情感障碍或分裂情感性障碍患者治疗反应的研究进行了综述。尽管针对分裂情感性障碍化疗的对照或非对照研究相对较少，但现有证据表明：（1）碳酸锂对分裂情感性躁狂和躁狂的初始治疗有效；（2）单独使用抗抑郁药、单独使用抗精神病药或它们的联合使用对分裂情感性抑郁和原发性抑郁的初始治疗均可能有效；（3）碳酸锂的预防性给药可能会降低分裂情感性躁狂和分裂情感性抑郁患者复发的频率和持续时间。因此，治疗研究表明，在对药物治疗的反应方面，分裂情感性障碍与原发性情感障碍非常相似。本文还介绍了本实验室的证据，即分裂情感性躁狂患者对锂盐或抗精神病药物治疗的反应比躁狂患者更慢。
